Filing Flows

Filing Flows › Companies › Ideaya Biosciences › Cash flow

Ideaya Biosciences cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$93.8M in Q3 2026 · −$350M over twelve months

Operating cash flow−$93.5M
Capital spending−$273K
Free cash flow−$93.8M

Analysis

In Q3 2026, Ideaya Biosciences generated −$93.5M of operating cash flow and spent $273K on capital projects, leaving free cash flow of −$93.8M. That is $236M less than in Q3 2025 ($142M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$347M; the largest uses were operating cash flow ($347M), other investing ($53.4M), capital spending ($2.4M); besides operations, cash came from shares issued ($191M), other financing ($175M); the cash balance fell by $37.0M.

Operating cash flow was −$93.5M against net income of −$126M. The largest differences: accrued liabilities +$21.2M, stock-based pay +$17.7M, payables −$7.5M.

Free cash flow

Ideaya Biosciences: free cash flow by quarterIdeaya Biosciences: free cash flow by quarter−$123MQ4 2024−$61.7MQ1 2025−$63.1MQ2 2025$142MQ3 2025−$90.8MQ4 2025−$76.1MQ1 2026−$89.1MQ2 2026−$93.8MQ3 2026
Operating cash flow less capital spending.
Ideaya Biosciences: operating cash flow against capital spendingIdeaya Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$122M$1.1MQ4 2024−$60.3M$1.3MQ1 2025−$62.5M$663KQ2 2025$142M$42KQ3 2025−$90.5M$333KQ4 2025−$75.2M$967KQ1 2026−$88.2M$866KQ2 2026−$93.5M$273KQ3 2026
Latest (Q3 2026): Operating cash flow −$93.5M, Capital spending $273K.

Capital allocation, year by year

Ideaya Biosciences: where the cash came from (up) and went (down), by fiscal yearIdeaya Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$55.8MFY2021: Shares issued $87.5MFY2021: Capital spending −$2.6M$87.5MFY2021FY2022: Operating cash flow −$87.2MFY2022: Shares issued $87.6MFY2022: Capital spending −$3.4M$87.6MFY2022FY2023: Operating cash flow −$115MFY2023: Shares issued $291MFY2023: Capital spending −$2.4M$291MFY2023FY2024: Operating cash flow −$248MFY2024: Shares issued $287MFY2024: Capital spending −$3.9M$287MFY2024FY2025: Operating cash flow −$71.1MFY2025: Shares issued $3.4MFY2025: Capital spending −$2.4M$3.4MFY2025
Over these 5 years operating cash flow totalled −$577M; the largest uses were operating cash flow ($577M) and capital spending ($14.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$839M
Debtnone
Net cash$839M
Cash runway2.4 years

Ideaya Biosciences is burning cash: its operations consume cash, a free cash flow of −$350M a year at the current rate against $839M of cash and investments: a runway of about 2.4 years before any new financing.

Where the cash came from and went

Ideaya Biosciences: sources (+) and uses (−) of cash, Q3 2026Ideaya Biosciences: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$93.5MOther investing$78.9MCash drawn (+) / kept (−)$11.1MShares issued$4.0MOther financing−$281KCapital spending−$273K
Ideaya Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Ideaya Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$347MShares issued$191MOther financing$175MOther investing−$53.4MCash drawn (+) / kept (−)$37.0MCapital spending−$2.4M

From profit to cash

Ideaya Biosciences: net income to operating cash flow, Q3 2026Ideaya Biosciences: net income to operating cash flow, Q3 2026Net income−$126MDepreciation & amortization$614KStock-based pay$17.7MPayables−$7.5MAccrued liabilities$21.2MContract assets$5.2MPrepaid and other assets−$4.6MOperating cash flow−$93.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$93.5M−$273K$4.0M$11.1M−$93.8M
Q2 2026−$88.2M−$866K$851K−$115M−$89.1M
Q1 2026−$75.2M−$967K$1.2M−$45.0M−$76.1M
Q4 2025−$90.5M−$333K$1.5M$186M−$90.8M
Q3 2025$142M−$42K$384K−$184M$142M
Q2 2025−$62.5M−$663K$410K$15.4M−$63.1M
Q1 2025−$60.3M−$1.3M$1.1M−$45.6M−$61.7M
Q4 2024−$122M−$1.1M$2.2M$316M−$123M

Ideaya Biosciences: income statement and cash flow

Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year). The chart follows the revenue to costs, profit and cash.

Ideaya Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.